File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cyclic combination chemotherapy in advanced adenocarcinoma of the lung: Comparison of two FAM schedules

TitleCyclic combination chemotherapy in advanced adenocarcinoma of the lung: Comparison of two FAM schedules
Authors
Issue Date1985
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1985, v. 14 n. 3, p. 282-283 How to Cite?
AbstractForty patients with advanced adenocarcinoma of the lung were treated by two FAM chemotherapy schedules. Group A (20 patients) received Futraful, adriamycin, and mitomycin C, and group B (20 patients) received 5-fluorouracil, adriamycin, and mitomycin C. The response/stabilization rate was greater for group B (4 partial responses + 4 cases of stable disease) than for group A (no responders + 5 cases of stable disease), and the median survival was longer for group B (32 weeks) than for group A (22 weeks), although the differences did not reach statistical significance in either case (P > 0.05). Myelotoxicity was mild in both schedules. Further studies of the two FAM schemes at an escalated dose would be worthwhile.
Persistent Identifierhttp://hdl.handle.net/10722/161686
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, WKen_US
dc.contributor.authorSo, SYen_US
dc.contributor.authorIp, Men_US
dc.contributor.authorYu, DYCen_US
dc.date.accessioned2012-09-05T05:13:58Z-
dc.date.available2012-09-05T05:13:58Z-
dc.date.issued1985en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1985, v. 14 n. 3, p. 282-283en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161686-
dc.description.abstractForty patients with advanced adenocarcinoma of the lung were treated by two FAM chemotherapy schedules. Group A (20 patients) received Futraful, adriamycin, and mitomycin C, and group B (20 patients) received 5-fluorouracil, adriamycin, and mitomycin C. The response/stabilization rate was greater for group B (4 partial responses + 4 cases of stable disease) than for group A (no responders + 5 cases of stable disease), and the median survival was longer for group B (32 weeks) than for group A (22 weeks), although the differences did not reach statistical significance in either case (P > 0.05). Myelotoxicity was mild in both schedules. Further studies of the two FAM schemes at an escalated dose would be worthwhile.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAdenocarcinoma - Drug Therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshDoxorubicin - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshLung Neoplasms - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMitomycinen_US
dc.subject.meshMitomycins - Therapeutic Useen_US
dc.subject.meshTegafur - Therapeutic Useen_US
dc.titleCyclic combination chemotherapy in advanced adenocarcinoma of the lung: Comparison of two FAM schedulesen_US
dc.typeArticleen_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid3922641-
dc.identifier.scopuseid_2-s2.0-0021910094en_US
dc.identifier.volume14en_US
dc.identifier.issue3en_US
dc.identifier.spage282en_US
dc.identifier.epage283en_US
dc.identifier.isiWOS:A1985AFV0100025-
dc.publisher.placeGermanyen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats